Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XNCR vs MGNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MGNX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

MGNX Overall Winner 6-Pillar Tally: XNCR 3 – 3 MGNX Matrix Metrics: XNCR 5 – 5 MGNX

As of Nov 16, 2026, MacroGenics, Inc. (MGNX) is the stronger overall head-to-head candidate over Xencor, Inc. (XNCR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas MGNX carries 43.6/100 (HOLD) at $2.12 (61.0x Forward P/E, -21.7% operating margin).

  • Growth vs. Quality Trade-Off: MGNX earns the overall head-to-head edge with a stronger Unified Composite Score (43.6/100 HOLD vs. XNCR 29.6/100 SELL) and 1.36β · 147% Vol risk profile, whereas XNCR leads top-line expansion (+454.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile MGNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XNCR vs MGNX
XNCR NASDAQ
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap $2.9B
TTM Revenue $200M
Forward P/E 68.0x
Beta / 30D Vol 1.21β · 87% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 62
RSI-14: 62.5 · SMA20: $32.16 · SMA50: $27.52
MGNX NASDAQ Head-to-Head Winner
MacroGenics, Inc.
Pharmaceutical Preparations
$2.12
-3.41% 1D
Market Cap $145.9M
TTM Revenue $175M
Forward P/E 61.0x
Beta / 30D Vol 1.36β · 147% Vol
Unified Composite Score
43.6 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.4%), weak momentum, RSI 28
RSI-14: 28.5 · SMA20: $2.50 · SMA50: $3.28

6-Pillar Scorecard Institutional Category Breakdown (XNCR 3 – 3 MGNX)

Columns: Metric · XNCR · MGNX
1. Valuation Multiples MGNX
Forward P/E 68.0x 61.0x
Trailing P/E 68.0x 61.0x
PEG Ratio N/M 0.01x
EV / Revenue 14.8x 0.4x
2. Growth & Scale XNCR
Revenue Growth (YoY) +454.9% +378.0%
Earnings Growth (YoY) +0.0% -70.4%
TTM Revenue (USD) $200M $175M
Market Cap $2.9B $145.9M
3. Profitability & Quality MGNX
Gross Margin -42.5% -0.7%
Operating Margin -72.7% -21.7%
Net Profit Margin -58.8% -8.3%
Return on Equity (ROE) -19.9% -225.9%
4. Balance Sheet & Cash Flow MGNX
Cash Generation (TTM) -$176M -$66M
Cash Flow Margin -88.0% -37.4%
Net Cash / Leverage $101M Net Debt (0.29x D/E) $79M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XNCR
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 79.0% (10th %ile) 52.8% (1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat XNCR
OpEx & R&D Intensity 30.2% of Rev ($61M) 21.0% of Rev ($37M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XNCR (5) vs MGNX (5)
Institutional Metric XNCR MGNX Criterion Row Edge
Market Capitalization
Scale
$2.9B $145.9M Larger Scale XNCR
Trailing P/E Ratio
Valuation
68.0x 61.0x Lower Multiple MGNX
Forward P/E Ratio
Valuation
68.0x 61.0x Lower Multiple MGNX
Revenue Growth (YoY)
Growth
+454.9% +378.0% Higher Growth XNCR
Operating Margin (TTM)
Profitability
-72.7% -21.7% Higher Margin MGNX
Net Profit Margin
Profitability
-58.8% -8.3% Higher Margin MGNX
Return on Equity (ROE)
Capital Efficiency
-19.9% -225.9% Higher ROE XNCR
52-Week Range Position
Momentum
84% ($10–$41) 21% ($1–$5) Stronger Trend XNCR
Beta / 30D Volatility
Risk Regime
1.21β · 87% Vol 1.36β · 147% Vol Lower Realized Risk XNCR
Unified Institutional Score
Composite Signal
29.6 / 100 (SELL) 43.6 / 100 (HOLD) Higher Composite MGNX
Trailing 12M Revenue (USD)
Operating Scale
$200M $175M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.5% -0.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.8x EV/Rev 0.01x PEG · 0.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$176M ($101M Net Debt (0.29x D/E)) -$66M ($79M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XNCR +90.46 pp
XNCR: +55.84% · MGNX: -34.62%
3M Horizon XNCR +88.18 pp
XNCR: +40.14% · MGNX: -48.04%
6M Horizon XNCR +273.12 pp
XNCR: +221.97% · MGNX: -51.15%
1Y Horizon XNCR +121.73 pp
XNCR: +154.54% · MGNX: +32.81%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period XNCR Revenue MGNX Revenue XNCR Op. Margin MGNX Op. Margin Margin Leader
FY2018 $40M $60M -195.5% -284.8% XNCR
FY2019 $160M $60M 8.8% -276.0% XNCR
FY2020 $120M $100M -62.6% -125.0% XNCR
FY2021 $280M $80M 15.9% -261.9% XNCR
FY2022 $160M $150M -50.1% -79.9% XNCR
FY2023 $170M $60M -75.8% -286.4% XNCR
FY2024 $110M $150M -161.5% -73.7% MGNX
FY2025 $130M $150M -141.4% -48.7% MGNX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XNCR BREAKOUT
58d in phase · OBV ACCUMULATION
Current IV 79.0%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MGNX BREAKDOWN
122d in phase · OBV NEUTRAL
Current IV 52.8%
IV Percentile 1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact MGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XNCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($61M)
90D Engineering Disclosures 0 Published
MGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $145.9M market capitalization and -21.7% operating margin.
OpEx & R&D Reinvestment 21.0% of Rev ($37M)
90D Engineering Disclosures 0 Published

Investor FAQ XNCR vs MGNX Key Questions & Quantitative Answers

As of Nov 16, 2026, MacroGenics, Inc. (MGNX) is the stronger overall head-to-head candidate over Xencor, Inc. (XNCR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas MGNX carries 43.6/100 (HOLD) at $2.12 (61.0x Forward P/E, -21.7% operating margin). Growth vs. Quality Trade-Off: MGNX earns the overall head-to-head edge with a stronger Unified Composite Score (43.6/100 HOLD vs. XNCR 29.6/100 SELL) and 1.36β · 147% Vol risk profile, whereas XNCR leads top-line expansion (+454.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile MGNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XNCR leads the Growth & Scale pillar: XNCR posts +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin), compared with MGNX at +378.0% YoY revenue growth and -70.4% YoY earnings growth on $175M TTM revenue (-0.7% gross margin, -21.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), XNCR cumulative revenue shifted +225.0% while MGNX shifted +150.0%. In operating R&D and SG&A reinvestment, XNCR deploys 30.2% of Rev ($61M) (0 90-day corporate R&D disclosures) versus 21.0% of Rev ($37M) (0 disclosures) for MGNX.

MGNX screens cheaper on headline valuation multiples. XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin), whereas MGNX trades at 61.0x Forward P/E, 61.0x Trailing P/E, 0.01x PEG, and 0.4x EV/Revenue (-37.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XNCR (-19.9% ROE) versus MGNX (-225.9% ROE) capital efficiency.

In options market volatility and institutional positioning, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk). By comparison, MGNX carries 52.8% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 147% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.